Market Place
Sourcing Support
Mineralys to Announce Q4 and 2024 Results on Feb 12, 2025
05 Feb 2025 //
GLOBENEWSWIRE
Mineralys Starts Lorundrostat Ph 2 For Sleep Apnea, Hypertension
08 Jan 2025 //
GLOBENEWSWIRE
Mineralys Therapeutics Reports Q3 2024 Financial Results & Update
11 Nov 2024 //
GLOBENEWSWIRE
Mineralys Therapeutics to Attend Upcoming Investor Conferences
05 Nov 2024 //
GLOBENEWSWIRE
Mineralys Therapeutics to Announce Q3 2024 Results on Nov 11
04 Nov 2024 //
GLOBENEWSWIRE
Mineralys Completes Enrollment in Lorundrostat Hypertension Trial
30 Oct 2024 //
GLOBENEWSWIRE
Mineralys To Host Virtual KOL Event On Resistant Hypertension
22 Oct 2024 //
GLOBENEWSWIRE
Mineralys Therapeutics Completes Enrollment In Advance-HTN Trial
25 Sep 2024 //
GLOBENEWSWIRE
Mineralys Therapeutics to Participate in the Wells Fargo Healthcare Conference
28 Aug 2024 //
GLOBENEWSWIRE
Mineralys Therapeutics Reports Q2 2024 Results And Corporate Update
13 Aug 2024 //
GLOBENEWSWIRE
Mineralys To Announce Q2 2024 Results On August 13
05 Aug 2024 //
GLOBENEWSWIRE
Mineralys Appoints Alexander Gold To Board Of Directors
14 Jun 2024 //
GLOBENEWSWIRE
Mineralys To Participate In Goldman Sachs Healthcare Conference
03 Jun 2024 //
GLOBENEWSWIRE
Mineralys Therapeutics Q1 2024 Financials And Update
09 May 2024 //
GLOBENEWSWIRE
Mineralys To Participate In BofA Healthcare Conference
06 May 2024 //
GLOBENEWSWIRE
Mineralys Q1 2024 Results, Call On May 9
02 May 2024 //
GLOBENEWSWIRE
Mineralys Reports Fourth Quarter and Full Year 2023 Financial Results
21 Mar 2024 //
GLOBENEWSWIRE
Mineralys to Announce Fourth Quarter and Full Year 2023 Financial Results
13 Mar 2024 //
GLOBENEWSWIRE
Mineralys Therapeutics Announces $120 Million Private Placement Financing
08 Feb 2024 //
GLOBENEWSWIRE
Mineralys to Participate in the Guggenheim Securities 6th Annual Conference
29 Jan 2024 //
GLOBENEWSWIRE
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer
04 Jan 2024 //
GLOBENEWSWIRE
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN
21 Dec 2023 //
GLOBENEWSWIRE
Mineralys Therapeutics Further Defines Endotype-Specific
11 Nov 2023 //
GLOBENEWSWIRE
Mineralys Therapeutics to Participate in Three Upcoming Conferences
09 Nov 2023 //
GLOBENEWSWIRE
Mineralys Therapeutics Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Mineralys Presents Post-Hoc Analysis from Target-HTN Phase 2 of Lorundrostat
02 Nov 2023 //
GLOBENEWSWIRE
Mineralys Therapeutics to Announce Third Quarter 2023 Financial Results
31 Oct 2023 //
GLOBENEWSWIRE
Mineralys Announces Poster Presentations at Two Conferences in November 2023
13 Oct 2023 //
GLOBENEWSWIRE
Mineralys Therapeutics Appointed Glenn Sblendorio and Daphne Karydas
14 Sep 2023 //
GLOBENEWSWIRE
Mineralys to Participate in the Cantor Fitzgerald Global Healthcare Conference
11 Sep 2023 //
GLOBENEWSWIRE
Mineralys Selected for Poster Presentation of Target-HTN Phase 2 Trial Results
05 Sep 2023 //
GLOBENEWSWIRE
Mineralys to Participate in the Wells Fargo Securities Healthcare Conference
29 Aug 2023 //
GLOBENEWSWIRE
Mineralys Reports Second Quarter 2023 Financial Results
07 Aug 2023 //
GLOBENEWSWIRE
Mineralys Therapeutics to Announce Second Quarter 2023 Financial Results
31 Jul 2023 //
GLOBENEWSWIRE
Mineralys Announces Expansion of Planned Phase 2 Trial of Lorundrostat
17 Jul 2023 //
GLOBENEWSWIRE
Mineralys Therapeutics to Participate in the Jefferies Healthcare Conference
31 May 2023 //
GLOBENEWSWIRE
Mineralys Therapeutics Reports 1Q 2023 FYR Results and Provides Corporate Update
15 May 2023 //
GLOBENEWSWIRE
Mineralys Announces First Patient Dosed the ADVANCE-HTN Trial of Lorundrostat
02 May 2023 //
GLOBENEWSWIRE
Mineralys Therapeutics to Announce First Quarter 2023 Financial Results
01 May 2023 //
GLOBENEWSWIRE
Mineralys Therapeutics to Participate in the Bank of America Securities 2023
27 Apr 2023 //
GLOBENEWSWIRE
Mineralys Reports Fourth Quarter and Full Year 2022 Financial Results
15 Mar 2023 //
GLOBENEWSWIRE
Mineralys Presents Positive Lorundrostat Results from Phase 2 Target-HTN Trial
04 Mar 2023 //
GLOBENEWSWIRE
Mineralys Therapeutics to Announce Fourth Quarter 2022 Financial Results
01 Mar 2023 //
GLOBENEWSWIRE
Mineralys Abstracts Selected to be Presented at (ACC.23/WCC) in March 2023
20 Feb 2023 //
GLOBENEWSWIRE
Mineralys Therapeutics Announces Closing of Initial Public Offering
14 Feb 2023 //
GLOBENEWSWIRE
Mineralys upsizes IPO to raise $192M for race with AstraZeneca
10 Feb 2023 //
FIERCE BIOTECH
Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering
09 Feb 2023 //
GLOBENEWSWIRE
Mineralys polishes $100M IPO ahead of phase 3 hypertension trial
19 Jan 2023 //
FIERCE BIOTECH
